🇺🇸 FDA
Pipeline program

Dipraglurant

ADX48621-203

Phase 2 small_molecule completed

Quick answer

Dipraglurant for Blepharospasm is a Phase 2 program (small_molecule) at Addex Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Addex Therapeutics
Indication
Blepharospasm
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials